RVXCF Stock News Resverlogix Corp (RVXCF) 0.7131 07/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Resverlogix Corp (RVXCF) 0.7131 $RVXCF

Restenosis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fzlqdr/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Restenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shire Plc - Resverlogix Corp. - CytoTools AG - Angelini Group - Viron Therapeutics, Inc. - AIM Therapeutics Inc. - CSPC NBP Pharmaceutical Co.,ltd - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/fzlqdr/restenosis

Resverlogix Board Update
PR Newswire - Tue Feb 11, 4:00PM CST
TSX Exchange Symbol: RVX

Zenith Epigenetics Board Update & Webcast Announcement
CNW Group - Tue Feb 11, 11:00AM CST
Zenith Epigenetics announced today that Arthur Higgins will be stepping down from the Board of Directors after fulfilling his commitment in helping Zenith Epigenetics to be established as a spin out company from Resverlogix Corp. Zenith Epigenetics' management and Board of Directors would like to thank Arthur for his commitment and positive input during this time.

Resverlogix Conference Call & Webcast Announcement
PR Newswire - Thu Feb 06, 3:30PM CST
TSX Exchange Symbol: RVX

CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.

Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist
PR Newswire - Thu Jan 02, 1:53PM CST
TSX Exchange Symbol: RVX

Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
PR Newswire - Mon Dec 23, 7:00AM CST
TSX Exchange Symbol: RVX

Global Encephalomyelitis Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/svxp6q/encephalomyelitis) has announced the addition of the "Encephalomyelitis - Pipeline Review, H2 2013" report to their offering. 'Encephalomyelitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalomyelitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalomyelitis. Scope - A snapshot of the global therapeutic scenario for Encephalomyelitis. - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalomyelitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Encephalomyelitis Therapeutics Development - Takeda Pharmaceutical Company Limited - Elan Corporation, plc - Hadasit Medical Research Services & Development Ltd - Compugen Ltd. - Array BioPharma Inc. - Resverlogix Corp. - KAHR medical Ltd. - Cognosci, Inc. - Encephalomyelitis - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Route of Administration - Assessment by Molecule Type Drug Profiles - IRX-5183 - KAHR-101 - KAHR-104 - COG-112 - Antiarrhythmic Drug - Phosphodiesterase Type 5 Inhibitors - Cholesterol Absorption Inhibitor - CGEN-15021 - CGEN-15091 - RVX-297 - AR-460770 - VCE-003 - VCE-004 - PP-090-45 - COG-133 - Thymulin - thymopentin - TAK-779 - Soluble Immune Response Suppressors - VLA-4 Antagonists - Activated Protein C For more information visit http://www.researchandmarkets.com/research/sv...lomyelitis

Stockboard Custom Reports on Resverlogix Corp. and Medicago Inc.
ACCESSWIRE - Tue Sep 03, 12:04PM CDT
Custom stock reports and email news alert service for Resverlogix Corp. (TSX:RVX) and Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) are now available on Stockboard.com

Resverlogix Announces a Corporate Update Conference Call & Webcast
PR Newswire - Thu Aug 29, 8:00AM CDT
TSX Exchange Symbol: RVX

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review - Latest Analysis
M2 - Wed Aug 21, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pv5b7/prediabetesimpai) has announced the addition of the "Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" report to their offering. Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" provides data on the Pre-Diabetes/Impaired Glucose Tolerance clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pre-Diabetes/Impaired Glucose Tolerance. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles - Arete Therapeutics Inc. - Bayer AG - Bioneer Corporation - Cadila Pharmaceuticals Ltd. - Daiichi Sankyo Company, Limited - Forest Laboratories, Inc. - Generex Biotechnology Corporation - Genfit SA - KineMed, Inc. - Limerick BioPharma, Inc. - Marico Limited - Merck & Co., Inc. - New Chapter, Inc. - Novartis AG - Novo Nordisk A/S - NuMe Health LLC - Resverlogix Corp. - Sanofi - Takeda Pharmaceutical Company Limited - UnitedHealth Group Incorporated For more information visit http://www.researchandmarkets.com/research/6p...betesimpai

Resverlogix Corporation is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com
Newsfile Corp - Fri Jul 05, 9:53AM CDT
full story)

IIROC Trade Resumption - Resverlogix Corp.
Newsfile Corp - Thu Jun 27, 1:10PM CDT
Trading resumes in:

Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
PR Newswire - Thu Jun 27, 1:00PM CDT
Resverlogix Corp. (TSX:RVX) today announced that its Phase 2b ASSURE clinical trial evaluating RVX-208 in high-risk cardiovascular patients with low high-density lipoprotein (HDL) did not meet its primary endpoint of a -0.6% change in percent atheroma volume as determined by intravascular ultrasound (IVUS). The RVX-208 treated group had -0.4% plaque regression (p= 0.08). RVX-208 is Resverlogix's first-in-class orally active BET-protein inhibitor.

IIROC Trade Halt - Resverlogix Corp.
Newsfile Corp - Thu Jun 27, 8:00AM CDT
The following issues have been halted by IIROC:

Zenith Epigenetics Corp. commences operations
PR Newswire - Mon Jun 03, 5:00PM CDT
Zenith Epigenetics Corp. ("Zenith" commenced operations today as an early stage research company. Zenith was formed as a result of a plan of arrangement (the "Arrangement" involving Resverlogix Corp. ("Resverlogix" , RVX Therapeutics Inc. ("Therapeutics" and Zenith pursuant to which Resverlogix spun-out Therapeutics to Zenith. Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.

Resverlogix Corp. announces completion of spin-out transaction
PR Newswire - Mon Jun 03, 4:45PM CDT
Resverlogix Corp. ("Resverlogix" (TSX: RVX) today announced the successful completion of its previously announced Plan of Arrangement under the Business Corporations Act (Alberta) (the "Arrangement" pursuant to which Resverlogix spun-out RVX Therapeutics Inc. ("Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.) ("Zenith" . Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.

RVXCF, TCEHY, WHX, TRMD, Removed From Naked Short Lists Today
M2 - Thu May 30, 9:02AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. RESVERLOGIX CORP (OTC:RVXCF), Tencent Holdings Ltd (OTC:TCEHY), Whiting USA Trust (NYSE:WHX), Torm A/S (NASDAQ:TRMD). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

Resverlogix Corp. shareholders approve plan of arrangement
PR Newswire - Tue May 28, 6:42PM CDT
Resverlogix Corp. ("Resverlogix" (TSX: RVX) announced today that holders ("Shareholders" of common shares of Resverlogix ("Resverlogix Shares" have approved the special resolution relating to the proposed spin-out of RVX Therapeutics Inc. ("Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.), a newly-incorporated company ("Newco" , pursuant to a plan of arrangement under the Business Corporations Act (Alberta) (the "Arrangement" . Upon completion of the Arrangement, shareholders of Resverlogix will own one common share of Resverlogix and one common share of Newco for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.

Resverlogix Announces Details of Anticipated Distribution of Newco Shares
PR Newswire - Mon May 27, 4:45PM CDT
Resverlogix Corp. (TSX:RVX) ("Resverlogix" announced that further to its previously announced Plan of Arrangement (the "Arrangement" to spin-out its subsidiary RVX Therapeutics Inc. ("RVX Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.), a newly-incorporated company ("Newco" , the record date for the distribution of common shares of Newco ("Newco Shares" is May 31, 2013. Upon completion of the Arrangement, shareholders of Resverlogix will own one common share of Resverlogix and one Newco Share for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 38

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 73

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 76

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 79

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 146

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 49

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 165

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 171

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 138

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Artisan Partners Asset Management's Q2 Performance and Highlights

Updated Category News Views 124

Artisan Partners Asset Management Inc. Reports Strong Q2 Performance Artisan Partners Asset Management Inc. (NYSE: APAM) recently showcased its financial success for the quarter ending June 30, 2025. The Company, renowned for its investment strategies, declared a quarterly dividend as part of its results presentation. This reflects Artisan's commitment to providing value...

Continue Reading
LVMH Reports Recent Share Transactions and Market Activity

Updated Category News Views 240

Understanding LVMH's Share Transactions Recently, LVMH Moët Hennessy Louis Vuitton disclosed share transactions conducted between exciting dates. This information was provided to the regulatory body, ensuring transparency for investors and industry stakeholders alike. As one of the leading companies in the luxury goods sector, LVMH’s transactions are always...

Continue Reading
Dynavax Technologies to Share Insights at Healthcare Conference

Updated Category News Views 160

Dynavax's Upcoming Participation in Healthcare Conference Dynavax Technologies Corporation (Nasdaq: DVAX), a prominent player in the biopharmaceutical landscape, is set to take part in a pivotal fireside chat at the 8th Annual Evercore Healthcare Conference. This insightful event will take place on an upcoming Tuesday at 2:10 p.m. ET. Investors and healthcare stakeholders...

Continue Reading
Growing Demand for 3D Surveillance Cameras by 2030

Updated Category News Views 301

The Growing Market for 3D Surveillance Cameras The global 3D surveillance camera market is on the brink of substantial growth, with forecasts indicating it could reach an impressive $7.92 billion by 2030. This surge is primarily fueled by increased investments in defense and public safety initiatives around the world. A key factor in this trend is the rising use of 3D...

Continue Reading
LVMH Stock Upgrade by BofA Signals Strong Growth Ahead

Updated Category News Views 317

LVMH Receives Positive Rating Upgrade from Bank of America Recently, Bank of America made headlines by upgrading LVMH shares to a Buy rating, moving it from a previous Neutral stance. This upgrade places the renowned luxury goods giant on its prestigious Europe 1 list of preferred investment ideas. Revised Price Targets Indicate Strong Potential The ratings agency has...

Continue Reading